Treatment for COVID in immunosuppressed people


Are you immunocompromised?


People with COVID-19 who are immunocompromised are at increased risk of progression to severe disease due to prolonged infection.

The immune system's contribution to clearing the infection is limited.

Although vaccines against COVID-19 are available, these may be inadequate for immunocompromised people.

We are conducting a clinical study of an oral medication to help potentially improve protection for immunocompromised people and thus assess the safety and efficacy of this medication.

To participate, you must:

  • Be aged 18 or over
  • Be immunocompromised

You will be reimbursed for expenses related to the study during your participation and you will be surrounded by a medical team throughout the process.

I want to apply to this clinical study


For more information, contact us at 819 346-2887 (Sherbrooke) or at 1-844-739-3439 (toll free), or fill the online form.

The study process in pictures


Step 1 | Before starting the study, we will take time to fully explain the selection process and the conduct of the study by phone.


Step 2 | After the initial phone interview, if you are still interested in taking part in a study, we schedule a preliminary meeting with you during which you may ask all the questions you wish and take the time you require to read over the consent form. This form explains, in detail, the different stages of each study.


Step 3 | You may make a decision at that time to move forward with or terminate the selection process. However, you are under no obligation to make an immediate decision. Based on briefing content, you may take the time necessary to come to a decision and consult with your personal physician or loved ones.


Step 4 | Depending on the nature of the study, some tests or medical examinations may be required. In the majority of cases, these tests or examinations are conducted on Diex Research premises based on your individual availability.


Step 5 | If you are eligible, you may then begin a clinical study with us.